期刊
EXPERIMENTAL HEMATOLOGY
卷 44, 期 11, 页码 1039-1043出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2016.07.012
关键词
-
资金
- Cole Foundation
- Canadian Institutes of Health Research (CIHR) Fellowship Award
- CIHR Graduate Scholarship Award
- Leukaemia & Blood Cancer New Zealand
- family of Marijanna Kumerich
- Canada Research Chair in Cancer Stem Cell Biology (Tier 2)
The involvement of the complement pathway in cancer is supported by a growing body of evidence, and yet its role in acute myeloid leukemia (AML) has not been extensively studied. We examined the expression of 87 genes in the complement, coagulation, and fibrinolysis-proteolytic pathways in 374 cytogenetically normal AML samples and observed that these samples can be divided into subgroups on the basis of complement gene expression. Three complement regulatory genes were linked to poor outcome as individual factors in a multivariate analysis (CFH, CFD, and SERPING1) in multiple cohorts. The combined expression of these genes was significantly associated with poorer overall survival in two cohorts of patients <60 years of age, independent of other factors (p <= 0.0004). For patients with an intermediate molecular risk, this three-gene risk marker enabled stratification of patients into prognostic subgroups with survival ranging from 17.4% to 44.1%. Thus, the expression of complement pathway genes is linked to outcome in AML, and a three-gene risk marker may improve the risk assessment of patients. Copyright (C) 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据